Combination of Sulindac and Dichloroacetate Kills Cancer Cells via Oxidative Damage

Sulindac is an FDA-approved non-steroidal anti-inflammatory drug with documented anticancer activities. Our recent studies showed that sulindac selectively enhanced the killing of cancer cells exposed to oxidizing agents via production of reactive oxygen species (ROS) resulting in mitochondrial dysf...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayyanathan, Kasirajan, Kesaraju, Shailaja, Dawson-Scully, Ken, Weissbach, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398923/
https://www.ncbi.nlm.nih.gov/pubmed/22866174
http://dx.doi.org/10.1371/journal.pone.0039949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398923/
https://www.ncbi.nlm.nih.gov/pubmed/22866174
http://dx.doi.org/10.1371/journal.pone.0039949

Ejemplares similares